Calistoga Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Formed around a preclinical program licensed from Icos, Calistoga Pharmaceuticals Inc. is developing multiple small-molecule inhibitors of the phosphoinositide-3 kinase pathway, a hot area in inflammation. Calistoga is targeting the PI3K delta isoform. Its initial clinical indications are hematological malignancies, asthma, and rheumatoid arthritis. A Phase I trial of CAL-101, an orally available, small-molecule inhibitor for inflammatory disease and cancer, is currently underway.
You may also be interested in...
It's Apples Versus Oranges in the PI3 Kinase Race
Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.
It's Apples Versus Oranges in the PI3 Kinase Race
Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Against Inflammation," features profiles of Asphleia Pharmaceuticals, Calistoga Pharmaceuticals, ProtAb Ltd., and Resolvyx Pharmaceuticals. Plus these Start-Ups Across Health Care: CG Therapeutics, Healionics, Mpathy Medical Devices and Pronostics.